findmyKOL

John Cush, MD

Enriched profile

Executive Editor, RheumNow.com; Professor of Internal Medicine, TCU Burnett School of Medicine · TCU Burnett School of Medicine

ORCIDNone on fileNPI
Region🇺🇸 Dallas, TX · South Central · United StatesSpecialtyRheumatologyFocusRheumatoid Arthritis
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2022Online presenceverified 2026Payments2021–2025NIH funding1995–1999Why? →

John Cush is Executive Editor, RheumNow.com; Professor of Internal Medicine, TCU Burnett School of Medicine at TCU Burnett School of Medicine. ClinicalTrials.gov lists 1 registered study with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

John Cush, MD, is Executive Editor, RheumNow.com at TCU Burnett School of Medicine (Fort Worth, TX) / RheumNow.com. The public record shows 98 publications with 10,888 citations (h-index 41), centered on Rheumatoid Arthritis. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 18 companies, 1 NIH-funded awards (1995–1999).

  • Top research focus: Rheumatoid Arthritis
  • 1 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 18 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Rheumatoid Arthritis1 trial

Research focus

OpenAlex concept fingerprint
Rheumatoid Arthritis

Drugs & molecules

across trials, industry payments and publications
Tremfyageneric · GuselkumabClinical trialsIndustry payments117PublicationsBimzelxgeneric · BimekizumabClinical trialsIndustry payments33PublicationsHumirageneric · AdalimumabClinical trialsIndustry payments28Publications

Works with

trial sponsors and companies reporting payments
Novartis Pharmaceuticals CorporationClinical trialsIndustry payments122Janssen Scientific Affairs, LLCClinical trialsIndustry payments117Abbvie Inc.Clinical trialsIndustry payments71

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
41h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials
18companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
1NIH grants · 1995–1999

Federally funded research awards.

View funding

Public positions

sourced statements on record

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

18 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2021)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    40.6%
    Opioid Agonist14.7%
    Tramadol Hcl100%
    Part D45 patients
    Gabapentinoids7.4%
    Gabapentin89%Pregabalin11%
    Part D<11 patients
  • Cancer & immunology

    21.7%
    Folate Analog Metabolic Inhibitor7.6%
    Methotrexate100%
    Part D36 patients
    TNF inhibitor5.7%
    Humira(Cf)36%Enbrel25%Humira(Cf) Pen21%Enbrel Sureclick17%
    Part D<11 patients
  • Musculoskeletal

    18.5%
    Xanthine oxidase inhibitor5.7%
    Allopurinol100%
    Part D20 patients
    Central alpha-2 Adrenergic Agonist5.2%
    Tizanidine Hcl100%
    Part D32 patients
2 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)8.1% facility · 91.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

1 NIH research award on record, funded 19951999 per NIH RePORTER. The latest:

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/cv/john-cush-md-1

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com

Mentions by others

where others cite or feature them
  • Other

    rheumnow.com/team

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →rheumnow.com
  • YouTube

    youtube.com/watch

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
2 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record
1 more award behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
1 more affiliation behind the reveal.Reveal →

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.